Biosimilars

Latest News

Infliximab Biosimilar Competition did not Improve Affordability for Patients
Infliximab Biosimilar Competition did not Improve Affordability for Patients

February 1st 2023

Investigators evaluated whether the availability of the biosimilar infliximab was linked to lower out-of-pocket costs using claims from the IBM MarketScan national data set of commercially insured patients.

WHO Guidelines on Evaluating Biosimilars Expand to Monoclonal Antibodies
WHO Guidelines on Evaluating Biosimilars Expand to Monoclonal Antibodies

February 1st 2023

Sintilimab Plus Bevacizumab Biosimilar Improved Response in Unresectable HCC
Sintilimab Plus Bevacizumab Biosimilar Improved Response in Unresectable HCC

January 31st 2023

Proposed Natalizumab Matches Reference Biosimilar in Phase 3 Data
Proposed Natalizumab Matches Reference Biosimilar in Phase 3 Data

January 31st 2023

Anti-TNF Biosimilars Yield Similar Results as Originator Drug in IBD Patients
Anti-TNF Biosimilars Yield Similar Results as Originator Drug in IBD Patients

January 31st 2023

Video Interviews

More News

© 2023 MJH Life Sciences

All rights reserved.